AbbVie Inc. (ABBV) stock analysis
Company overview and business model
Source fact: AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox Cosmetic for the treatment of glabellar lines, crow's feet, forehead lines, and platysma bands; Juvederm Collection to treat volume loss in the temples, undereye, cheeks, chin, lips and lower face; Vraylar to treat schizophrenia, bipolar disorder, and depressive disorder; Duodopa to treat Parkinson's disease; Ubrelvy to treat migraine; Qulipta for episodic and chronic migraine; and Vyalev for the treatment of motor fluctuations, as well as Botox Therapeutic to treat chronic migraine, overactive bladder, spasticity, cervical dystonia, and other conditions. In addition, the company offers Ozurdex for visual impairment; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; and other eye care products, including Refresh/Optive, Xen, Durysta, and Restasis. Further, it provides Mavyret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; and Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Classification: NYSE · Healthcare · Drug Manufacturers - General
Revenue and growth
Source fact: Revenue was USD 61.16 billion for the period ending 2025-12-31.
Caverian calculation: Revenue changed +8.6% (FY2025 vs FY2024).
Profitability
Source fact: Net income was USD 4.23 billion in the latest reported period.
Source metric: Reported net margin was 6.9%.
Balance sheet and liquidity
Source fact: Cash and equivalents were USD 5.23 billion.
Source fact: Total debt was USD 67.50 billion.
Source metric: Current ratio was 0.67x.
Cash-flow analysis
Source fact: Operating cash flow was USD 19.03 billion.
Source fact: Free cash flow was USD 17.82 billion.
Valuation
Source metrics: Trailing P/E 75.24x; Forward P/E 16.12x; Price to sales 7.19x; EV/EBITDA 17.13x.
Caverian model output: Value score was 43/100.
Competitive position
Classification: Peer context: Drug Manufacturers - General within Healthcare.
Caverian model output: Quality score was 60/100.
Caverian model output: Growth score was 47/100.
Material risks
Caverian model interpretation: Watch out: short-term cash may not cover short-term bills.
Caverian calculation: Altman Z-score was 2.42 (grey zone).
Caverian calculation: Piotroski F-score was 7/9.
Data sources and freshness
Freshness: This report uses a stored upstream snapshot; statement periods are shown alongside the figures.
Methodology and limitations
Facts reproduce stored upstream fields. Calculations derive only from the displayed stored statements. Model outputs are Caverian interpretations, not investment advice or a buy/sell recommendation.
How Caverian approaches valuation · Sources and product principles